<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To investigate the toxicity profile, activity, and pharmacokinetics of a novel L-<z:chebi fb="0" ids="33838">nucleoside</z:chebi> analog, troxacitabine (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BCH</z:e>-4556), in patients with advanced <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Patients with refractory or relapsed <z:hpo ids='HP_0011009'>acute</z:hpo> myeloid (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) or lymphocytic (ALL) <z:hpo ids='HP_0001909'>leukemia</z:hpo>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), or <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blastic phase</z:e> (<z:mp ids='MP_0005481'>CML</z:mp>-BP) </plain></SENT>
<SENT sid="2" pm="."><plain>Troxacitabine was given as an intravenous infusion over 30 minutes daily for 5 days </plain></SENT>
<SENT sid="3" pm="."><plain>The starting dose was 0.72 mg/m(2)/d (3.6 mg/m(2)/course) </plain></SENT>
<SENT sid="4" pm="."><plain>Courses were given every 3 to 4 weeks according to toxicity and antileukemic efficacy </plain></SENT>
<SENT sid="5" pm="."><plain>The dose was escalated by 50% until grade 2 toxicity was observed, and then by 30% to 35% until the dose-limiting toxicity (DLT) was defined </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Forty-two patients (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>: 31 patients; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>: six patients [five <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> + one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>]; ALL: four patients; <z:mp ids='MP_0005481'>CML</z:mp>-BP: one patient) were treated </plain></SENT>
<SENT sid="7" pm="."><plain>Median age was 61 years (range, 23 to 79 years), and 29 patients were males </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0010280'>Stomatitis</z:hpo> and <z:e sem="disease" ids="C0549410" disease_type="Disease or Syndrome" abbrv="">hand-foot syndrome</z:e> were the DLTs </plain></SENT>
<SENT sid="9" pm="."><plain>The MTD was defined as 8 mg/m(2)/d </plain></SENT>
<SENT sid="10" pm="."><plain>The pharmacokinetic behavior of troxacitabine is linear over the dose range of 0.72 to 10.0 m/m(2) </plain></SENT>
<SENT sid="11" pm="."><plain>Approximately 69% of troxacitabine was excreted as unchanged drug in the urine </plain></SENT>
<SENT sid="12" pm="."><plain>Marrow <z:mpath ids='MPATH_133'>hypoplasia</z:mpath> occurred between days 14 and 28 in 73% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="13" pm="."><plain>Three complete remissions and one partial remission were observed in 30 assessable <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients </plain></SENT>
<SENT sid="14" pm="."><plain>One <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patient achieved a hematologic improvement </plain></SENT>
<SENT sid="15" pm="."><plain>A patient with <z:mp ids='MP_0005481'>CML</z:mp>-BP achieved a return to <z:hpo ids='HP_0011010'>chronic</z:hpo> phase disease </plain></SENT>
<SENT sid="16" pm="."><plain>CONCLUSION: Troxacitabine has a unique metabolic and pharmacokinetic profile and significant antileukemic activity </plain></SENT>
<SENT sid="17" pm="."><plain>DLTs were <z:hpo ids='HP_0010280'>stomatitis</z:hpo> and <z:e sem="disease" ids="C0549410" disease_type="Disease or Syndrome" abbrv="">hand-foot syndrome</z:e> </plain></SENT>
<SENT sid="18" pm="."><plain>Troxacitabine merits further study in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
</text></document>